Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
Tesaro, Inc.
Mario Negri Institute for Pharmacological Research
Bristol-Myers Squibb
Hoffmann-La Roche
Fondazione Michelangelo
Sumitomo Pharma America, Inc.
ERYtech Pharma
Centus Biotherapeutics Limited
Blokhin's Russian Cancer Research Center
AbbVie
Clovis Oncology, Inc.
New Mexico Cancer Research Alliance
Amgen
Synta Pharmaceuticals Corp.
GlaxoSmithKline